Level 4. Full Text Article Data Abstraction Form for Cardiac Surgery Studies

CARDIAC SURGERY

1. Is this a RCT/Quasi-RCT Yes No	that reports data on cardi	ac surgery? If no, STOP	ABSTRACTION
2. Is this a quasi-RCT? If ye Yes, describe	s, briefly describe details		
3. List the number of subject			
	N Intervention	N Control	Comments
Subjects randomized			
Subjects receiving			
assigned therapy			
Subjects lost to follow-up or withdrawn			
4. Briefly describe inclusion ischemic/thrombotic/emboli Brief description Yes, at least one exclusion/in	c events, also check the ti	ick box indicating that.	
5. Was a standard of care de Yes, briefly describe No	fined? (e.g., special trans	fusion protocols or care by	y the same cardiac surgery team)
6. Type (s) of surgery perfe	ormed (for adults) (chec	k all that apply)	
Multiple surgeries CABG			
Cardiac transplantation			
Single valve repair/replacem	nent .		
Any aortic	lent		
All Other, specify			
No cardiac surgery for adult	s		
7. <u>Type (s) of surgery perfe</u> Reoperation (any type)	ormed (for child) (check	all that apply)	
Correction of congenital hea	rt disease		
All other, specify			
No surgery perfomed in chil	d	· · · · · · · · · · · · · · · · · · ·	
1.0 sargery performed in clin			

8. rFVIIa Dose Information

rFVIIa Dose	Dose Units (e.g. mg or ug/kg)	Uniform, Mean, or Median Dose? (use codes U, MN, MD)	SD (or Range or IQR), if applicable	Number of rFVIIa doses	Comments (e.g. specify if variance is range or IQR)

9. Time/Location of rFVIIa administration	
Before or at onset of surgery	
During surgery, or after, but while still in OR	
Postoperatively (e.g. in ICU), but prior to any reoperation	
Return from reoperation for bleeding	
All other, describe	
Not reported or Unclear	
Not reported or Oriclear	

Patient demographics and other information

10. If different than number of subjects randomized to each group, specify the number of patients with reported demographic/baseline data:

N Intervention	N Control	Comments	

Variable	Mean (or Median) Intervention	SD (or Range or IQR Intervention	Mean (or Median) Control	SD (or Range or IQR) Control	Comments (e.g. specify other variable, units, mean/med, SD/range/IQR)
11. Age					
12. Gender					
13. Weight (or BMI or					
body surface area, specify					
units)					
14. Other demographic 1,					
specify					
15. Other demographic 2,					
specify					
16. Other demographic 3,					
specify					
17. Other demographic 4,					
specify					

Variable	N Intervention	N Control	Comments (e.g. specify other variable)
18. Emergency surgery			
19. Previous cardiac surgery			
20. History of thrombotic/embolic			
events, specify			
21. Diabetes			
22. Renal failure			
23. CHF			
24. COPD			
25. Hypertension			
26. Other comorbidity 1, specify			
27. Other comorbidity 2, specify			
28. Other comorbidity 3, specify			

Results 29. If different than the number of subjects randomized to each group, specify the number of patients with reported results data:

N Intervention	N Control	Comments

Continuous variable

Event	Mean (or Median) Intervention	SD (or Range or IQR) Intervention	Mean (or Median) Control	SD (or Range or IQR) Control	Time Frame	Comments (e.g. specify other variable, units, mean/med, SD/range/IQR)
30. RBCs transfused in 24h						
(packed units)						
31. FFP transfused						
32. Blood loss (or chest tube						
drainage) (mLs)						
33. OR time (hours)						
34. Other result 1, specify						
35. Other result 2, specify						
36. Other result 3, specify						
37. Other result 4, specify						
38. Other result 5, specify						
39. Other result 6, specify						

Results categorical variables

Event	N Intervention	N Control	Comments (e.g. specify other variable)
40. In-hospital mortality			
41. Need for return to			
OR/surgical re-exploration			
42. Number of patients			
requiring transfusions, specify			
further			
43. Other result 7, specify			
44. Other result 8, specify			
45. Other result 9, specify			
46. Other result 10, specify			
47. Other result 11, specify			
48. Other result 12, specify			

Harm information

49	Were	harms	measured?
47.	WCIC	114111115	THEASULEU!

49. Were harms measured? No. If checked here, STOP abstraction

50. Was there an explicit follow up time for determination Yes, describe	n of harms?
51. How were harms identified?	
Prospectively, describe	
Retrospectively, describe	
Both prospectively and retrospectively	
Not reported or Unclear	
Not reported of Official	

52. Did the study specifically a administration? Yes, specify how	ttempt to	make the de	etermination that ha	rms were	secondary	to rFVIIa
53. If harms were adjudicated in Blinded panel Other	n any way	, specify ho	ow.			
54. If different than the number harms data:	r of subjec	ets randomi	zed to each group, s	pecify the	e number o	f patients with reported
N Intervention		N Contro	ol .		Commer	nts
Undifferentiated Thomboeml	bolic Har	ms (i.e.)		
		vents (n)	N Intervention	N Co	ntrol	Comments
55. All thromboembolic		()		1		
events						
	•		•			,
Arterial Thromboembolic Ha	rms					
Event	Total E	vents (n)	N Intervention	N Co	ntrol	Comments
56. All arterial						
thromboembolic events						
(without further delineation)						
57. Myocardial Infarction						
58. Stroke						
59. Mesenteric thrombosis						
60. Renal infarct 61. Other arterial						
thromboembolic event,						
specify type in comments box						
specify type in comments box	1					
Venous Thromboembolic Har	rms					
Event	Total E	vents (n)	N Intervention	N Co	ntrol	Comments
62. All venous						
thromboembolic events						
(without further delineation)						
63. Pulmonary embolism						
64. Deep vein thrombosis						
65. Mesenteric vein						
thrombosis						
66. Portal vein thrombosis						
67. Thrombosis in right-side chamber of heart						
68. Other venous						
thromboembolic event,						
specify type in comments box						
Transfer July 1			L			
Instrument-related Thrombo	embolic I	Harms				
Event	Total E	vents (n)	N Intervention	N Cor	ntrol	Comments
69. All instrument-related						
thromboembolic events						
(without further delineation)						
70. ECMO-related						
thromboembolic events 71. Arterial line clot						
11. Alterial line Clut	1		1	1		

72. Venous line clot		
73. Other instrument-related		
event, specify type in		
comments box		

Other NON-thromboembolic Harms

Event	Total Events (n)	N Intervention	N Control	Comments
74. Multi-organ failure				
75. Cardiogenic				
shock/requirement for				
balloon pump				
76. Respiratory failure/ARDS				
77. Renal failure				
78. Sepsis				
79. DIC				
80. Other event #1, specify				
81. Other event #2, specify				
82. Other event #3, specify				
83. Other event #4, specify				
84. Other event #5, specify				

85. Do you have any other comments? Please use this space to describe any relevant information that could not be collected on this form.